In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
This year marks the fourth year that AACR will be inducting newly elected Fellows into its AACR Academy. The...
This post, originally featured on the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center blog “Cancer Matters," applauds the launch...
Myeloma is the third most common blood cancer in the United States, arising in the plasma cells of the...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today
In the third post of the “Meet the Chairs” series, Anna Barker, PhD, chair of the AACR Scientist↔Survivor Program...
AACR is the proud Scientific Partner for Stand Up To Cancer (SU2C), and for Colorectal Cancer Awareness Month, we...
On March 7, the AACR co-hosted its first, local advocacy event with the Moffitt Cancer Center in Tampa, Florida....
A recent study in the AACR’s journal Cancer Epidemiology, Biomarkers & Prevention found an association between glycemic index (a...
Last week, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of crizotinib (Xalkori)...
In the second post of the "Meet the Chairs" series, Mark Stewart, PhD, chair of the AACR's Associate Member...